Human LOXL2 knockout HeLa cell pellet (ab279227)
Overview
-
Product name
Human LOXL2 knockout HeLa cell pellet
See all LOXL2 kits -
Product overview
Abcam’s knockout cell pellets give you access to native proteins, without the need to culture cells. Our knockout cell pellets are prepared from our single-gene knockout cell lines and provide an additional offering to our cell lysates.
Cells are snap-frozen to provide high quality pellets that are suitable for extraction with alternative lysis buffers or for preparation of lysates from subcellular fractions. Our knockout cell pellets are suitable for a variety of applications, including PCR, gene expression profiling and DNA library preparation. -
Parental Cell Line
HeLa -
Organism
Human -
Mutation description
Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 4. -
Passage number
Knockout validation
Sanger Sequencing, Western Blot (WB)Notes
Pellet size: 5 million cells/vial.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.
Tested applications
Suitable for: WBmore detailsProperties
-
Storage instructions
Store at -80°C. Please refer to protocols. -
Components 1 kit Human LOXL2 knockout HeLa cell pellet 1 vial Human wild-type HeLa cell pellet 1 vial -
Research areas
-
Cell type
epithelial -
Disease
Adenocarcinoma -
Gender
Female -
STR Analysis
Amelogenin X D5S818: 11, 12 D13S317: 12, 13.3 D7S820: 8, 12 D16S539: 9, 10 vWA: 16, 18 TH01: 7 TPOX: 8, 12 CSF1PO: 9, 10
Target
-
Tissue specificity
Expressed in many tissues. Highest expression in reproductive tissues, placenta, uterus and prostate. -
Sequence similarities
Belongs to the lysyl oxidase family.
Contains 4 SRCR domains. -
Post-translational
modificationsThe lysine tyrosylquinone cross-link (LTQ) is generated by condensation of the epsilon-amino group of a lysine with a topaquinone produced by oxidation of tyrosine. -
Cellular localization
Secreted > extracellular space. - Information by UniProt
-
Alternative names
- LOR 2
- LOR2
- LOX L2
see all
Properties
-
Storage instructions
Store at -80°C. Please refer to protocols. -
Components 1 kit Human LOXL2 knockout HeLa cell pellet 1 vial Human wild-type HeLa cell pellet 1 vial -
Research areas
-
Cell type
epithelial -
Disease
Adenocarcinoma -
Gender
Female -
STR Analysis
Amelogenin X D5S818: 11, 12 D13S317: 12, 13.3 D7S820: 8, 12 D16S539: 9, 10 vWA: 16, 18 TH01: 7 TPOX: 8, 12 CSF1PO: 9, 10
Images
-
Western blot - Human LOXL2 knockout HeLa cell pellet (ab279227)
Lane 1: Wild-type HeLa cell lysate (20 µg)
Lane 2: LOXL2 knockout HeLa cell lysate (20 µg)
Lane 3: HeLa treated with 0.5nM CoCl2 for 6 hours whole cell lysate (20 µg)
Lane 4: Untreated HeLa cell lysate (20 µg)
Lanes 1-4: Merged signal (red and green). Green - ab179810 observed at 105 kDa. Red - loading control, ab8245 observed at 37 kDa.
ab179810 Anti-LOXL2 antibody [EPR12733] - C-terminal was shown to specifically react with LOXL2 in wild-type HeLa cells. Loss of signal was observed when knockout cell line ab261804 (knockout cell lysate ab257168) was used. Wild-type and LOXL2 knockout samples were subjected to SDS-PAGE. ab179810 and Anti-GAPDH antibody [6C5] - Loading Control (ab8245) were incubated overnight at 4°C at 1 in 500 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye®800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye®680RD) preadsorbed (ab216776) secondary antibodies at 1 in 10000 dilution for 1 hour at room temperature before imaging.
-
Sanger Sequencing - Human LOXL2 knockout HeLa cell pellet (ab279227)Allele-1: 1 bp insertion in exon 4
-
Sanger Sequencing - Human LOXL2 knockout HeLa cell pellet (ab279227)Allele-2:
-
Sanger Sequencing - Human LOXL2 knockout HeLa cell pellet (ab279227)Allele-3:
-
Sanger Sequencing - Human LOXL2 knockout HeLa cell pellet (ab279227)Allele-4: